Weight loss drug sales boost Novo Nordisk shares

CommSec’s Tom Piotrowski says Novo Nordisk shares rose up by three per cent after the pharmaceutical company reported a rise in its third-quarter sales and profits driven by weight loss drugs Wegovy and Ozempic. “It was a busy night for earning,” Mr Piotrowski told Sky News Australia. Mr Piotrowski said Novo Nordisk, an organisation at the front of conversations around weight loss, had a good session up three per cent. He said Wegovy and Ozempic sales led to a "record quarter" for Novo Nordisk. Presented by CommSec.